Promaxo

Executive Summary

Promaxo is developing a portable, low-field MRI system designed for in-office use by urologists, aiming to transform prostate cancer diagnosis and treatment. By integrating imaging, AI, and robotic guidance, the platform enables targeted biopsies and therapies outside traditional hospital settings, improving accessibility, convenience, and diagnostic accuracy. Founded in 2016 and based in Oakland, CA, the company targets a significant unmet need in prostate cancer care, where current MRI access is limited by cost and infrastructure. Promaxo's technology received FDA 510(k) clearance in 2021, and the company is now focused on commercial adoption and expanding clinical indications. While still private and early-stage, Promaxo's innovative approach positions it to capture a niche in the urology device market, though execution risks related to market acceptance and reimbursement remain.

Upcoming Catalysts (preview)

• Q3 2026Continued commercial rollout and partnership with urology clinics60% success
• Q1 2027FDA clearance for expanded indications (e.g., other cancer types)40% success
• Q4 2026Strategic partnership or distribution agreement with a major medical device company50% success